Patents by Inventor Jeffrey S. Albert

Jeffrey S. Albert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted benzimidazoles, their preparation and their use as pharmaceuticals
    Patent number: 11981657
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: May 14, 2024
    Assignee: EPIGENETIX, INC.
    Inventors: Mehrnaz Pourashraf, Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20230120413
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: May 13, 2022
    Publication date: April 20, 2023
    Inventors: Mehrnaz POURASHRAF, Guillaume JACQUEMOT, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • Substituted benzimidazoles, their preparation and their use as pharmaceuticals
    Patent number: 11365186
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: June 21, 2022
    Assignee: EPIGENETIX, INC.
    Inventors: Mehrnaz Pourashraf, Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20210107893
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: May 22, 2020
    Publication date: April 15, 2021
    Inventors: Mehrnaz POURASHRAF, Guillaume JACQUEMOT, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
    Patent number: 10836742
    Abstract: This application relates to N-substituted bicyclic lactams of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to the N-substituted bicyclic lactams of formula (I) and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: November 17, 2020
    Assignee: Neomed Institute
    Inventors: Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20200299262
    Abstract: This application relates to aryl-substituted dihydroquinolinones of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to aryl-substituted dihydroquinolinones and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: October 28, 2019
    Publication date: September 24, 2020
    Inventors: Guillaume JACQUEMOT, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • SUBSTITUTED IMIDAZOPYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20200299291
    Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: October 29, 2019
    Publication date: September 24, 2020
    Inventors: Mehrnaz POURASHRAF, Marc-Andre BEAULIEU, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • Substituted benzimidazoles, their preparation and their use as pharmaceuticals
    Patent number: 10703740
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: July 7, 2020
    Assignee: Neomed Institute
    Inventors: Mehrnaz Pourashraf, Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • N-SUBSTITUTED BICYCLIC LACTAMS, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20200024253
    Abstract: This application relates to N-substituted bicyclic lactams of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to the N-substituted bicyclic lactams of formula (I) and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: August 11, 2016
    Publication date: January 23, 2020
    Inventors: Guillaume JACQUEMOT, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
    Patent number: 10501459
    Abstract: This application relates to substituted imidazopyridines, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted imidazopyridines of Formula I and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 10, 2019
    Assignee: Neomed Institute
    Inventors: Mehrnaz Pourashraf, Marc-Andre Beaulieu, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
    Patent number: 10501438
    Abstract: This application relates to aryl-substituted dihydroquinolinones of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to aryl-substituted dihydroquinolinones and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: December 10, 2019
    Assignee: Neomed Institute
    Inventors: Guillaume Jacquemot, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • Rac inhibitors
    Patent number: 10472352
    Abstract: The present invention relates to compounds that act as pan-Rac inhibitors, compositions including the compounds, and methods of using the compounds. In particular, the compounds are useful for treating certain cancers such as breast cancer.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 12, 2019
    Assignee: GENEYUS LLC
    Inventors: Marc Lippman, Erik Goka, Shawn D. Johnstone, Malken Bayrakdarian, William Brown, Jeffrey S. Albert
  • RAC INHIBITORS
    Publication number: 20190031647
    Abstract: The present invention relates to compounds that act as pan-Rac inhibitors, compositions including the compounds, and methods of using the compounds. In particular, the compounds are useful for treating certain cancers such as breast cancer.
    Type: Application
    Filed: July 25, 2018
    Publication date: January 31, 2019
    Applicant: Geneyus LLC
    Inventors: Marc LIPPMAN, Erik GOKA, Shawn D. JOHNSTONE, Malken BAYRAKDARIAN, William BROWN, Jeffrey S. ALBERT
  • SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20180237417
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: August 12, 2016
    Publication date: August 23, 2018
    Inventors: Mehrnaz POURASHRAF, Guillaume JACQUEMOT, Stephen CLARIDGE, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20180230130
    Abstract: This application relates to aryl-substituted dihydroquinolinones of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to aryl-substituted dihydroquinolinones and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Application
    Filed: August 11, 2016
    Publication date: August 16, 2018
    Inventors: Guillaume JACQUEMOT, Malken BAYRAKDARIAN, Shawn JOHNSTONE, Jeffrey S. ALBERT, Andrew GRIFFIN
  • OXAZOLO[5,4-C]QUINOLIN-2-ONE COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20160039842
    Abstract: The present invention relates to compounds useful as bromodomain inhibitors. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compounds and compositions in the treatment of various diseases and disorders.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 11, 2016
    Inventors: Jeffrey S. ALBERT, Shawn JOHNSTONE, Paul JONES
  • Alkyl sulfoxide quinolines as NK-3 receptor ligands
    Patent number: 7964733
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: Jeffrey S. Albert, Gerard M. Koether, Cristobal Alhambra, James Kang, Thomas R. Simpson, James Woods, Yan Li
  • Alkylsulphonamide quinolines
    Patent number: 7608628
    Abstract: Compounds of Formula II wherein R1, A, R2, R3, R4, R5, R8, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: October 27, 2009
    Assignee: AstraZeneca AB
    Inventors: Thomas R. Simpson, James Kang, Jeffrey S. Albert, Cristobal Alhambra, Gerald M. Koether, James Woods, Yan Li
  • Alkylnitrile Quinolines as Nk-3 Receptor Ligands
    Publication number: 20080306110
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: September 19, 2006
    Publication date: December 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li
  • Alkylpyridyl Quinolines as Nk3 Receptor Modulators
    Publication number: 20080287492
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and p are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: August 9, 2006
    Publication date: November 20, 2008
    Applicant: AstraZeneca AB
    Inventors: Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li